81 related articles for article (PubMed ID: 17724473)
1. P-TEFb inhibitors interfere with activation of p53 by DNA-damaging agents.
Radhakrishnan SK; Bhat UG; Halasi M; Gartel AL
Oncogene; 2008 Feb; 27(9):1306-9. PubMed ID: 17724473
[TBL] [Abstract][Full Text] [Related]
2. A novel transcriptional inhibitor induces apoptosis in tumor cells and exhibits antiangiogenic activity.
Radhakrishnan SK; Gartel AL
Cancer Res; 2006 Mar; 66(6):3264-70. PubMed ID: 16540679
[TBL] [Abstract][Full Text] [Related]
3. Flavopiridol potentiates the cytotoxic effects of radiation in radioresistant tumor cells in which p53 is mutated or Bcl-2 is overexpressed.
Hara T; Omura-Minamisawa M; Kang Y; Cheng C; Inoue T
Int J Radiat Oncol Biol Phys; 2008 Aug; 71(5):1485-95. PubMed ID: 18640498
[TBL] [Abstract][Full Text] [Related]
4. Gene-specific requirement for P-TEFb activity and RNA polymerase II phosphorylation within the p53 transcriptional program.
Gomes NP; Bjerke G; Llorente B; Szostek SA; Emerson BM; Espinosa JM
Genes Dev; 2006 Mar; 20(5):601-12. PubMed ID: 16510875
[TBL] [Abstract][Full Text] [Related]
5. Ribosomal protein S27-like, a p53-inducible modulator of cell fate in response to genotoxic stress.
Li J; Tan J; Zhuang L; Banerjee B; Yang X; Chau JF; Lee PL; Hande MP; Li B; Yu Q
Cancer Res; 2007 Dec; 67(23):11317-26. PubMed ID: 18056458
[TBL] [Abstract][Full Text] [Related]
6. Regulation of metastasis-related gene expression by p53: a potential clinical implication.
Sun Y; Wicha M; Leopold WR
Mol Carcinog; 1999 Jan; 24(1):25-8. PubMed ID: 10029407
[TBL] [Abstract][Full Text] [Related]
7. Chromatin immunoprecipitation-on-chip reveals stress-dependent p53 occupancy in primary normal cells but not in established cell lines.
Shaked H; Shiff I; Kott-Gutkowski M; Siegfried Z; Haupt Y; Simon I
Cancer Res; 2008 Dec; 68(23):9671-7. PubMed ID: 19047144
[TBL] [Abstract][Full Text] [Related]
8. Proapoptotic compound ARC targets Akt and N-myc in neuroblastoma cells.
Radhakrishnan SK; Halasi M; Bhat UG; Kurmasheva RT; Houghton PJ; Gartel AL
Oncogene; 2008 Jan; 27(5):694-9. PubMed ID: 17724478
[TBL] [Abstract][Full Text] [Related]
9. B-MYB is required for recovery from the DNA damage-induced G2 checkpoint in p53 mutant cells.
Mannefeld M; Klassen E; Gaubatz S
Cancer Res; 2009 May; 69(9):4073-80. PubMed ID: 19383908
[TBL] [Abstract][Full Text] [Related]
10. Hypersensitivity to chromium-induced DNA damage correlates with constitutive deregulation of upstream p53 kinases in p21-/- HCT116 colon cancer cells.
Hill R; Leidal AM; Madureira PA; Gillis LD; Cochrane HK; Waisman DM; Chiu A; Lee PW
DNA Repair (Amst); 2008 Feb; 7(2):239-52. PubMed ID: 18024214
[TBL] [Abstract][Full Text] [Related]
11. Small molecular weight variants of p53 are expressed in human melanoma cells and are induced by the DNA-damaging agent cisplatin.
Avery-Kiejda KA; Zhang XD; Adams LJ; Scott RJ; Vojtesek B; Lane DP; Hersey P
Clin Cancer Res; 2008 Mar; 14(6):1659-68. PubMed ID: 18310316
[TBL] [Abstract][Full Text] [Related]
12. Increases in sequence specific DNA binding by p53 following treatment with chemotherapeutic and DNA damaging agents.
Tishler RB; Calderwood SK; Coleman CN; Price BD
Cancer Res; 1993 May; 53(10 Suppl):2212-6. PubMed ID: 8485705
[TBL] [Abstract][Full Text] [Related]
13. Induction of apoptosis by pectenotoxin-2 is mediated with the induction of DR4/DR5, Egr-1 and NAG-1, activation of caspases and modulation of the Bcl-2 family in p53-deficient Hep3B hepatocellular carcinoma cells.
Shin DY; Kim GY; Kim ND; Jung JH; Kim SK; Kang HS; Choi YH
Oncol Rep; 2008 Feb; 19(2):517-26. PubMed ID: 18202802
[TBL] [Abstract][Full Text] [Related]
14. A single recombinant adenovirus expressing p53 and p21-targeting artificial microRNAs efficiently induces apoptosis in human cancer cells.
Idogawa M; Sasaki Y; Suzuki H; Mita H; Imai K; Shinomura Y; Tokino T
Clin Cancer Res; 2009 Jun; 15(11):3725-32. PubMed ID: 19458054
[TBL] [Abstract][Full Text] [Related]
15. Human bladder cancer cells undergo cisplatin-induced apoptosis that is associated with p53-dependent and p53-independent responses.
Konstantakou EG; Voutsinas GE; Karkoulis PK; Aravantinos G; Margaritis LH; Stravopodis DJ
Int J Oncol; 2009 Aug; 35(2):401-16. PubMed ID: 19578756
[TBL] [Abstract][Full Text] [Related]
16. Breast cancer amplified sequence 2, a novel negative regulator of the p53 tumor suppressor.
Kuo PC; Tsao YP; Chang HW; Chen PH; Huang CW; Lin ST; Weng YT; Tsai TC; Shieh SY; Chen SL
Cancer Res; 2009 Dec; 69(23):8877-85. PubMed ID: 19903847
[TBL] [Abstract][Full Text] [Related]
17. The genetics of the p53 pathway, apoptosis and cancer therapy.
Vazquez A; Bond EE; Levine AJ; Bond GL
Nat Rev Drug Discov; 2008 Dec; 7(12):979-87. PubMed ID: 19043449
[TBL] [Abstract][Full Text] [Related]
18. [Can they heal p53].
Jeanteur P
Bull Cancer; 2000 Feb; 87(2):131-2. PubMed ID: 10705280
[No Abstract] [Full Text] [Related]
19. Differential sensitivity of malignant glioma cells to methylating and chloroethylating anticancer drugs: p53 determines the switch by regulating xpc, ddb2, and DNA double-strand breaks.
Batista LF; Roos WP; Christmann M; Menck CF; Kaina B
Cancer Res; 2007 Dec; 67(24):11886-95. PubMed ID: 18089819
[TBL] [Abstract][Full Text] [Related]
20. Restoring wtp53 activity in HIPK2 depleted MCF7 cells by modulating metallothionein and zinc.
Puca R; Nardinocchi L; Bossi G; Sacchi A; Rechavi G; Givol D; D'Orazi G
Exp Cell Res; 2009 Jan; 315(1):67-75. PubMed ID: 18996371
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
